Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
1200 participants
INTERVENTIONAL
2025-05-30
2028-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
NCT03896724
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
NCT07183371
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
NCT05155579
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
NCT06080243
Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants
NCT01231503
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We plan to evaluate, using the R21/MM malaria vaccine as a model system, how age at first vaccine dose and time intervals between doses modify the immunogenicity of the vaccine and the ensuant efficacy in protecting infants against clinical Plasmodium falciparum malaria.
Healthy male or female infants 6 to 7 weeks of age will be randomized to one of three different immunization schedule cohorts: a) a "compressed" conventional schedule at 6-10-14 weeks of age; b) a "relaxed" schedule at 2-4-6 months of age; c) a "relaxed" schedule at 3-6-9 months of age. Participants in each immunization schedule cohort will be randomized in a ratio of 3:1 to receive 4 doses of either R21/MM or placebo with a 4th dose to be administered at 15 months of age.
Infants randomized to the respective immunization schedule categories will receive co-administered routine EPI vaccines. The study will include the provision of a three dose R21/MM compressed schedule to all participants randomized to the placebo arms upon completion of the study at Month 27 of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Infants will be randomized within each immunization schedule category to a group assignment to either receive the R21/MM or placebo; neither the blinded study staff nor the parent/legal guardian will know whether the infant will receive the R21/MM or placebo.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Compressed 6-10-14 Week Schedule: R21/MM Malaria Vaccine
Participants will receive R21/MM malaria vaccination at 6, 10, and 14 weeks of age, co-administered with hexavalent vaccine, pneumococcal conjugate vaccine (PCV), and oral rotavirus vaccine (RV). At 9 months of age participants will receive measles-rubella (MR) vaccine, yellow fever (YF) vaccine, and typhoid conjugate vaccine (TCV).
Participants will receive a booster dose of R21/MM malaria vaccine at 15 months of age co-administered with the 2nd dose of measles-rubella vaccine and meningococcal A conjugate vaccine (MenA).
R21 Matrix-M (R21/MM) Malaria Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Compressed 6-10-14 Week Schedule: Placebo
Participants will receive placebo at 6, 10, and 14 weeks of age, co-administered with hexavalent vaccine, PCV, and oral RV. At 9 months of age participants will receive MR and YF vaccines, and TCV.
Participants will receive a booster dose of placebo at 15 months of age co-administered with the 2nd dose of MR vaccine and MenA vaccine.
Participants will receive R21/MM malaria vaccination at 27, 28, and 29 months of age (after completion of the study).
Placebo
Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Relaxed 2-4-6 Month Schedule: R21/MM Malaria Vaccine
Participants will receive R21/MM malaria vaccination at 2, 4, and 6 months of age co-administered with hexavalent vaccine, PCV, and oral RV. At 9 months of age participants will receive MR and YF vaccines and TCV.
Participants will receive a booster dose of R21/MM malaria vaccine at 15 months of age co-administered with the 2nd dose of MR vaccine and MenA vaccine.
R21 Matrix-M (R21/MM) Malaria Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Relaxed 2-4-6 Month Schedule: Placebo
Participants will receive placebo at 2, 4, and 6 months of age co-administered with hexavalent vaccine, PCV, and oral RV. At 9 months of age participants will receive MR and YF vaccines, and TCV.
Participants will receive a booster dose of placebo at 15 months of age co-administered with the 2nd dose of MR vaccine and MenA vaccine.
Participants will receive R21/MM malaria vaccination at 27, 28, and 29 months of age (after completion of the study).
Placebo
Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Relaxed 3-6-9 Month Schedule: R21/MM Malaria Vaccine
Participants will receive R21/MM malaria vaccination at 3, 6, and 9 months of age. Participants will receive the hexavalent vaccine, PCV, and oral RV at 6 weeks, 10 weeks, and 3 months of age. At 9 months of age participants will receive MR and YF vaccines and TCV.
Participants will receive a booster dose of R21/MM malaria vaccine at 15 months of age co-administered with the 2nd dose of MR vaccine and the MenA vaccine.
R21 Matrix-M (R21/MM) Malaria Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Relaxed 3-6-9 Month Schedule: Placebo
Participants will receive placebo at 3, 6, and 9 months of age. Participants will receive the hexavalent vaccine, PCV, and oral RV at 6 weeks, 10 weeks, and 3 months of age. At 9 months of age participants will receive MR and YF vaccines and TCV.
Participants will receive a booster dose of placebo at 15 months of age co-administered with the 2nd dose of MR vaccine and the MenA vaccine.
Participants will receive R21/MM malaria vaccination at 27, 28, and 29 months of age (after completion of the study).
Placebo
Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R21 Matrix-M (R21/MM) Malaria Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
Placebo
Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
Hexavalent Vaccine
Administered by intramuscular injection. Each dose of 0.5 mL contains:
* Diphtheria Toxoid \> 30 IU
* Tetanus Toxoid \> 40 IU
* B. pertussis (whole cell) \> 4 IU
* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg
* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU
* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]
Pneumococcal Polysaccharide Conjugate Vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
Rotavirus, Live Attenuated (Oral) Vaccine
Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
Measles and Rubella Vaccine
Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
Meningococcal A conjugate vaccine
Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
Yellow Fever vaccine
Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Typhoid Conjugate vaccine
Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infants must have been born full-term (at ≥37 weeks of gestation) and \> 2500 grams at birth.
* Immunization schedule Cohorts 1, 2, and 3: : Male and female infants 42-49 days (inclusive) of age at time of enrollment. For infants in Cohort 1, randomization to receive vaccine dose 1 (Groups 1 and 2 of R21/MM or placebo, respectively) will occur at 42-49 days of age. For infants in Cohort 2, randomization to receive vaccine dose 1 (Groups 3 and 4 of R21/MM or placebo, respectively) will occur at 2 months (56-63 days of age). For infants in Cohort 3, randomization to receive vaccine dose 1 (Groups 5 and 6 of R21/MM or placebo, respectively) will occur at 3 months (84-91 days of age).
* The participant's parent/guardian must be willing to avoid travel, particularly in the 28 days after each study vaccination, must confirm willingness to contact the study team in the event of unexpected/unavoidable travel and, for the safety cohort, must confirm availability for the home visits to be conducted by a field worker to collect solicited AEs over the 7 days (day of vaccination and 6 subsequent days) following each study vaccine.
* The participant's parent/guardian must confirm willingness to bring their child to the study clinic / local health care clinic, and capacity to contact the study team in the event the subject has any illnesses or other health concerns during the study.
* Participants who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol (e.g. return for follow-up visits) may be enrolled in the study.
Exclusion Criteria
* Clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial.
* At time of enrollment, any infant who has received any dose of the hexavalent/pentavalent vaccines, pneumococcal vaccine, rotavirus vaccine, IPV or has received more than one dose of oral polio virus or more than one dose of hepatitis B vaccine.
* Weight-for-height/length Z score of less than -3 or other clinical signs of malnutrition.
* Infant with major congenital defects.
* The infant has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of ≤ 5.0 g/dL.
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
* Any confirmed or suspected immunosuppressive or immunodeficient state (including HIV or asplenia) or known maternal HIV infection (no HIV testing will be routinely done by the study team).
* Administration of immunoglobulins and/or any blood products/blood transfusion from birth to time of planned administration of the vaccine candidate.
* Previous vaccination of participant or biological mother with a malaria vaccine.
* Participation in another research study involving receipt of an investigational product or planned use during the study period.
* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
42 Days
49 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Serum Institute of India PVT LTD (SII)
UNKNOWN
Agilis
UNKNOWN
Pharmassist Ltd
INDUSTRY
MCT-CRO
UNKNOWN
Cytespace
UNKNOWN
PATH
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de Recherche en Science de la Santé (IRSS)
Bobo-Dioulasso, , Burkina Faso
Groupe de Recherche Action en Santé (GRAS)
Ouagadougou, , Burkina Faso
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVIA 108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.